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Abstract
We profiled and analyzed 283 metabolites representing eight
major classes of molecules including Lipids, Carbohydrates,
Amino Acids, Peptides, Xenobiotics, Vitamins and Cofactors,
Energy Metabolism, and Nucleotides in mouse liver of 104
inbred and recombinant inbred strains. We find that metabo-
lites exhibit a wide range of variation, as has been previously
observed with metabolites in blood serum. Using genome-wide
association analysis, we mapped 40% of the quantified metab-
olites to at least one locus in the genome and for 75% of the
loci mapped we identified at least one candidate gene by local
expression QTL analysis of the transcripts. Moreover, we vali-
dated 2 of 3 of the significant loci examined by adenoviral
overexpression of the genes in mice. In our GWAS results, we
find that at significant loci the peak markers explained on
average between 20 and 40% of variation in the metabolites.
Moreover, 39% of loci found to be regulating liver metabolites
in mice were also found in human GWAS results for serum
metabolites, providing support for similarity in genetic regula-
tion of metabolites between mice and human. We also inte-
grated the metabolomic data with transcriptomic and clinical
phenotypic data to evaluate the extent of co-variation across
various biological scales.
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Introduction
Metabolites are produced in the cell as a result of various enzy-
matic reactions and in part reflect the metabolic state of the cell
(Sabatine et al, 2005; Sreekumar et al, 2009). Recent advances in
high throughput technologies such as mass spectrometry and
nuclear magnetic resonance have allowed investigators and clini-
cians to comprehensively measure and quantify such molecules
with reasonable precision in tissues (Ellis et al, 2007; Wang
et al, 2010). Investigators have begun to utilize these technolo-
gies to explore the relationships between metabolite levels and
disease-related traits for the identification of biomarkers and
elucidation of mechanisms underlying disease (Newgard et al,
2009). These initial reports, primarily involving metabolites
measured in the human blood serum, have shown that some
metabolite levels are associated with complex disease phenotypes
and may be used to assess risk factors for complex diseases
such as diabetes (Wang et al, 2011), and frequently exhibit large
heritability (Shah et al, 2009; Nicholson et al, 2011) and genetic
variation due to only a handful of loci in the genome (Gieger
et al, 2008; Illig et al, 2010; Suhre et al, 2011; Wang et al,
2011). In addition, efforts have begun to integrate metabolomic
data with other molecular phenotypes such as transcriptomes
and proteomes with the goal of elucidating the relevant path-
ways underlying complex disease phenotypes (Ferrara et al,
2008; Connor et al, 2010; Inouye et al, 2010).
The goal of the current study was to characterize the genetic
landscape of liver metabolites in rodents. We quantified and
performed genome-wide association analysis (GWAS) of the liver
metabolome in the Hybrid Mouse Diversity Panel (HMDP)
comprised of 104 classical inbred strains and recombinant inbred
strains (Bennett et al, 2010). While human metabolomic studies
are largely restricted to either blood serum or urine, using experi-
mental organism such as the mouse, it is possible to examine
other tissues. Moreover, since the HMDP strains are inbred (and,
therefore, renewable), metabolite levels can be readily integrated
with other measured traits and molecular phenotypes. In the pres-
ent study, we examined the extent of genetic regulation of metab-
olite levels in the liver of HMDP strains. These strains have been
densely genotyped and, in most cases, fully sequenced and, thus,
following correction of population structure, we were able to
finely map loci controlling a large fraction of the measured
metabolites. We also examined the extent of liver metabolites
covariation with both liver transcriptomic data and 58 cardio-
metabolic traits.
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Results
Metabolite profiling
Using mass spectrometry (Metabolon Inc., Durham, NC) we exam-
ined liver metabolites in male mice across 104 inbred strains
comprising the HMDP (for details of metabolite profiling see Materi-
als and Methods). This methodology enabled us to quantify a
comprehensive set of 283 metabolites present in mouse liver tissues
across the HMDP panel. This set comprised of a diverse group of
small molecules derived from the metabolism of four major class of
macromolecules (Lipids, Carbohydrates, Proteins, Nucleic acids) as
well as vitamins and cofactors, xenobiotics, and molecules related
to energy metabolism. The transformed metabolite measurements
can be found in Supplementary Table S1. We classified the 283
metabolites according to the primary metabolic pathway from which
they are derived. The major classes identified were: lipid metabo-
lism (“Lipids”), amino acid metabolism (“Amino Acids”), carbohy-
drate metabolism (“Carbohydrates”), nucleotide metabolism
(“Nucleotides”), peptide-derived molecules (“Peptides”), xenobiotics
(“Xenobiotics”), vitamins and cofactors (“Cofactors”), and energy
metabolism (“Energy”). From the 283 metabolites, the Lipids class
represented the highest fraction (121 metabolites) followed by
Amino Acids (78), Carbohydrates and Nucleotides (23 each),
Peptides (10), Energy (7), and Xenobiotics (5) (Supplementary Fig
S1). The metabolites exhibited significant correlations both within
and between classes (Fig 1 and Supplementary Table S2). Overall,
1,639 pairwise correlations were significant after Bonferoni correc-
tion for multiple comparison (P-value < 1.25e-06), from which 68%
(1,112/1,639) belonged to the within class pairs and 32% (527/
1,639) belonged to between class correlations across all classes
(Supplementary Table S2) reflecting shared biochemical pathways
or regulatory interactions for metabolites across different classifica-
tions. We also observed that the extent to which metabolites corre-
lated with other metabolites depended on the classification of the
metabolites. Metabolites classified as “Cofactors and Vitamins”,
“Energy”, and “Xenobiotics” exhibited the least and metabolites
classified as “Lipids”, “Amino Acids”, and “Carbohydrates” had the
largest number of significant within and between class correlations.
Genetic regulation of metabolites
Figure 2A shows the variation of each of the 283 metabolites across
the HMDP mice (each metabolite is ordered by its z-score in the
HMDP population). A high degree of variability, as evident by the
wide distribution of z-scores across all the eight major classes,
reflects the influence of both genetic and environmental factors
regulating metabolite levels. In order to explore the extent of genetic
controls of metabolite variation, we compared the variance across
the HMDP mice to the variance among five biological replicates in
the commonly used C57BL/6J (B6) strain. Both the mean and
median of variance for B6 mice were smaller than the entire popula-
tion (mean of 0.36 in B6 versus 0.51 in HMDP, and median variance
of 0.12 versus 0.30 in HMDP) suggesting the presence of genetic
factors affecting metabolite variation in HMDP.
To identify the loci regulating the metabolite variation, we
applied the genome-wide association analysis approach utilizing
107,145 SNPs from the Broad Institute and Wellcome Trust Center
database (http://www.broadinstitute.org/mouse/hapmap) which
had a minor allele frequency >5% in the HMDP population of 104
inbred and recombinant inbred mouse strains. With this panel of
SNPs, we performed genome-wide association for each of the 283
metabolites using Efficient Mixed Modeling Algorithm (EMMA) that
corrects for population structure and genetic relatedness among
strains (Kang et al, 2008b). To avoid false positive associations
resulting from over 20 million statistical tests performed in the
GWAS, we set the statistical significance threshold at the genome-
wide FDR cutoff of 5% corresponding to the association P-value of
7.6 × 106 (Storey & Tibshirani, 2003). This corresponds roughly to
the genome-wide significance level obtained using simulation analy-
ses (Bennett et al, 2010). Significant linkage disequilibrium blocks
Figure 1. Correlation heatmap for the 283 metabolites measured in
HMDP mouse liver.
The color bars on the top and the side of the heatmap represent the different
classes as labeled. Within the heatmap, red represents a positive correlation, blue
represents a negative correlation, and white represents a non-significant
correlation.
Figure 2. Summary of GWAS results for metabolites.
A Metabolite variation in the HMDP mice. The Z-score for each metabolite across the 104 HMDP mice is plotted along the X-axis. Each row represents one of the 283
metabolites measured. Each metabolite is represented by the color shown in the color key.
B Genome-wide plot for the most significant GWAS result (pyridoxate metabolite). The dotted line depicts the genome-wide significance threshold.
C Distribution of the number of loci regulating metabolites.
D GWAS results for succinylcarnitine, which mapped to 18 distinct loci across the genome. The dotted line depicts the genome-wide significance threshold. The
asterisks depict the significant loci.
▶
Molecular Systems Biology 10: 730 | 2014 ª 2014 The Authors
Molecular Systems Biology Genetic regulation of mouse liver metabolites Anatole Ghazalpour et al
2
Figure 2.
ª 2014 The Authors Molecular Systems Biology 10: 730 | 2014
Anatole Ghazalpour et al Genetic regulation of mouse liver metabolites Molecular Systems Biology
3
occur among the HMDP strains (Frazer et al, 2007; Keane et al,
2011) and in such blocks (defined as SNPs exhibiting an R-squared
> 0.5), we only consider the peak SNP (i.e. the most significant
SNP) as the true association.
Using 5% FDR as the genome-wide cutoff (P-value =
7.6 × 106), we were able to identify 240 significant associations,
from which 12 are expected to be false positives, for 119 of the 283
metabolites (Table 1 lists the top 10 associations and Supplemen-
tary Table S3 lists all the significant associations). Based on the peak
SNP, the 240 significant associations corresponded to 227 distinct
loci across the genome. The strongest association was found for
pyridoxate mapping to the locus at 58.2 Mb on chromosome 1 with
the P-value of 1.6e-28 (Fig 2B). The largest number of genome-
wide significant associations found at a single marker was on
chromosome 19 at 46.7 Mb, corresponding to three metabolites
(methylmalonate, malonate, and gulono-1,4-lactone). Defining the
size of the locus as a 2 Mb window (1 Mb on each side of the peak
SNP), there were 45 candidate genes residing at this locus including
Elovl3 (3-keto acyl-CoA synthase) which functions in the fatty acid
elongation pathway. From the 119 metabolites with at least one
significant association, 73 metabolites mapped to only one locus
and the remaining 46 metabolites mapped to more than one locus
(Fig 2C). The largest number of loci identified for any metabolite
was for succinylcarnitine which mapped to more than 10 loci in the
genome (Fig 2D). Calculation of percent variance explained for the
peak markers underlying the 227 loci revealed that on average each
significant peak SNP explained 26% of variation (Fig 3). We also
found four loci that explained more than 50% of metabolite varia-
tions: the locus on chromosome 1 at 58.2 Mb explains 72% of pyri-
doxate variation, the locus on chromosome 7 at 152.4 Mb explains
52% of gamma-aminobutyrate (GABA) variation, the locus on chro-
mosome 8 at 119 Mb explains 51% of malonate variation, and the
locus on chromosome 9 at 106.5 Mb explains 50% of N-acetylgluta-
mate variation.
To assess the genetic complexity of metabolites in each class, we
evaluated both the strength of the association P-value and the
percent variance explained by the significant loci identified and
found no significant differences between the eight major classes
(Fig 3 and Supplementary Fig S2). Using Fisher’s Exact Test, we
also found no over- or under-representation of eight major classes
of metabolites among the 119 loci mapped.
Candidate gene prioritization
The number of candidate genes influencing metabolite levels at
each associated locus varies from a few to dozens, depending
upon the level of linkage disequilibrium. To help narrow down
the list of candidate genes and to gain further insight into the
molecular mechanism regulating metabolite levels, we integrated
data from both the public database and from gene expression
microarray analyses with the metabolite data. For the latter, we
have previously reported the transcriptome profiling of the HMDP
mice (Bennett et al, 2010) using Affymetrix HT_MG-430A gene
expression microarray platform consisting of over 23 thousand
probes, as well as mapping of transcript levels using EMMA
(Ghazalpour et al, 2011).
To identify potential candidate genes affecting metabolite levels,
we took two different approaches: First we reasoned that if any
enzyme or a gene is involved in the production or turnover of a
metabolite within the cell, it will be functionally linked to the
metabolite and both qualify as a potential candidate gene and vali-
date the identified locus as a true association based on prior knowl-
edge. For this, we examined public databases for biochemical
pathways and, for each metabolite, we asked if any of the genes that
are physically located at the locus to which metabolite maps are co-
annotated with the metabolite. We performed this analysis using
two independent public databases KEGG (http://www.genome.jp/
kegg) and HMDB (http://www.hmdb.ca) (Wishart et al, 2009).
From the total of 240 associations, 3 associations (1%) were found
to be validated by the public database annotation of biochemical
pathways. The three validated associations included pyridoxate
mapping to the chromosome 1 locus containing aldehyde oxidase 1
(Aox1), glycerol 3-phosphate mapping to chromosome 2 locus
containing glycerol-3-phosphate dehydrogenase 2 (Gpd2), and N-
acetylglutamate mapping to chromosome 9 locus containing amino-
acylase 1 (Acy1).
In the second approach we searched in the expression data for
any local eQTL that coincided with each of the 227 loci identified for
the metabolites. As such, local eQTLs are useful in narrowing
down the list of candidate genes at each locus. The local eQTLs
utilized in this study were identified using the 5% FDR cutoff
(P-value = 1.7 × 105) and map within a megabase of the gene
whose expression is affected. From the 227 loci identified, local eQTL
Table 1. Top 10 GWAS results
Metabolite Class Pathways
GWAS
P-value Chromosome Base pair
Pyridoxate Cofactors and vitamins Vitamin B6 metabolism 1.66E-28 1 58,236,240
Glucarate (saccharate) Cofactors and vitamins Ascorbate and aldarate metabolism 7.84E-17 4 118,382,970
N-acetylglutamate Amino acids Glutamate metabolism 1.09E-15 9 106,563,342
Malonate (propanedioate) Lipids Mevalonate metabolism 2.59E-15 8 119,096,872
Glycerate Carbohydrates Glycolysis, gluconeogenesis, pyruvate metabolism 2.11E-14 12 43,670,942
Methylmalonate (MMA) Amino acids Valine, leucine and isoleucine metabolism 6.50E-14 8 119,096,872
Succinylcarnitine Energy Krebs cycle 1.16E-13 3 144,100,853
Methylmalonate (MMA) Amino acids Valine, leucine and isoleucine metabolism 4.79E-13 19 46,764,525
Methylmalonate (MMA) Amino acids Valine, leucine and isoleucine metabolism 8.84E-13 1 32,385,974
Kynurenate Amino acids Tryptophan metabolism 3.83E-11 2 134,733,767
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analysis identified at least one candidate gene for 174 of the loci
(~75% of the loci). We report these 174 loci along with the local
eQTL candidate genes in Supplementary Table S4, and, below, we
describe two specific examples in which the metabolite locus candi-
date gene was supported by the local eQTL data (Fig 4A and B). The
first example is for the “hypoxanthine” metabolite. This metabolite,
which belongs to the “Nucleotide” class of metabolites, can be
produced in the cell either from xanthine or by degradation of
purine. The former reaction is catalyzed by the enzyme xanthine
oxidase (also known as xanthine dehydrogenase or Xdh), which is
encoded by the Xdh gene located on chromosome 17. In HMDP mice,
there is a genetic variation in this gene that affects the transcript
levels of this gene, with a significant eQTL. It appears that this varia-
tion is also affecting the hypoxanthine pool in the liver of HMDP
mice as hypoxanthine maps to the same locus as both the Xdh gene
and the mRNA variation of Xdh (Fig 4A). The second example is for
the locus on chromosome 2 where glycerol-3-phosphate dehydroge-
nase 2 gene (Gpd2) resides. The protein product of this gene, which
is localized to the mitochondrial inner membrane, functions in the
glycerophospholipid metabolism pathway, and catalyzes the conver-
sion of glycerol-3-phosphate (G3P) to dihydroxyacetone phosphate,
using FAD as a cofactor. HMDP mice have a DNA variation which
affects the transcription of this gene, as is evident by the local eQTL
for Gpd2. In the metabolite GWAS results, G3P, the Gpd2 substrate,
maps to the exact location as Gpd2 mRNA, suggesting that the same
variation that affects Gpd2 transcription also affects the G3P abun-
dance in the liver of HMDP mice (Fig 4B).
Candidate gene validation
Searching public databases coupled with transcriptome and metabo-
lome mapping data resulted in a list of candidate genes regulating
metabolites in liver. In order to evaluate the validity of our candi-
date gene identification approach, we performed biological valida-
tion of selected candidate genes by adenovirus overexpression.
Since our aim was to demonstrate proof of principle rather than
Figure 3. Genetic regulation of metabolite variation.
Comparison of percent metabolite variance explained by the peak maker in the GWAS analysis across various classes of metabolites. The largest variance explained was
observed for the Vitamins and Cofactors class with the peak marker explaining 72% of the pyridoxate variation.
Figure 4. Validation of metabolite loci by the local eQTLs.
A Co-localization of xanthine dehydrogenase mRNA (red) with its product
hypoxanthine (blue), at the chromosome 17 locus where the xanthine
dehydrogenase gene, Xdh1 resides.
B Co-localization of glycerol-3-phosphate dehydrogenase 2 mRNA (red) with
its substrate glycerol 3-phosphate (blue), at the chromosome 2 locus where
glycerol-3-phosphate dehydrogenase 2 gene (Gpd2) resides.
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novel gene discovery, our selection of candidates was based on
prior biochemical knowledge. The three candidate genes selected
for this purpose were Gpd2, Aox1, and Acy1, and based on mapping
locations they were predicted to affect glycerol-3-phosphate,
N-acetylglutamate, and pyridoxate metabolite levels in the liver,
respectively. For each experiment, 4 C57BL/6J mice were injected
with adenovirus expressing the candidate gene of interest and
6 days post injection the liver tissues were collected and metabolites
profiled by the same methodology used for profiling metabolites of
the HMDP strains (for details see Materials and Methods). An
adenovirus expressing LacZ was used as a control.
As shown in Fig 5A, Gpd2 overexpression by adenovirus in mice
resulted in a significant reduction of glycerol-3-phosphate levels in
liver compared to the control mice. These results were consistent
with the GWAS data in which mice with the high-expressor geno-
types for Gpd2 had significantly reduced G3P levels.
In the second experiment, adenoviral overexpression of Acy1
gene in the liver of mice also resulted in changes predicted by the
GWAS results. As shown in Fig 5B, GWAS data predicted that mice
with the allele expressing higher levels of Acy1 have significantly
lower N-acetylglutamate levels compared to mice carrying the
variant that lowers Acy1 levels. Consistent with this observation,
adenoviral overexpression of Acy1 in mice significantly lowered the
N-acetylglutamate levels in the liver, establishing the causal rela-
tionship between the Acy1 gene and N-acetylglutamate metabolite.
Lastly, GWAS data predicted that mice with higher Aox1 tran-
script levels would have elevated pyridoxate levels. We observed
slightly elevated levels of pyridoxate in mice overexpressing Aox1
(Fig 5C) although these changes were not statistically significant.
We note that 28 other local eQTL, including two other amylase gene
family members, Aox3 and Aox4, were present at the locus to which
pyridoxate levels mapped and, thus, it is possible that the locus
contains multiple genes influencing pyridoxate levels.
In summary, 2 of 3 validation experiments confirmed the effect
of the candidate genes identified in the GWAS study, and the third
was suggestive.
Comparison of mouse and human loci
An immediate question arising from the results obtained in metabo-
lite profiling of mouse liver data is whether the loci identified corre-
spond to the loci regulating metabolite levels in human. Although
no current human study is available in which liver metabolites have
been measured, Illig et al recently published GWAS results for 163
blood serum metabolites in two large European populations (Illig
et al, 2010) and subsequently Suhre et al published a meta-analysis
of these GWAS results and expanded the metabolite profiles to over
250 (Suhre et al, 2011). As the second report includes more metabo-
lites we compared our results with theirs. In this meta-analysis,
authors reported 37 significant loci passing the genome-wide signifi-
cance. From these 37 loci, 17 loci regulated 17 separate single
metabolite levels and 20 loci regulated the ratio of pair of metabo-
lites. To investigate human-mouse concordance in genetic regula-
tion of metabolites, we first asked from the 37 significant loci in
human how many replicated in our study. Of these, eleven metabo-
lites were also measured in our study and from these eleven, five
metabolites (succinylcarnitine, isobutyrylcarnitine, proline, carni-
tine, and isovalerylcarnitine) had at least one significant locus in the
mouse GWAS results. When searched for the human syntenic loci in
mouse for these five metabolites, succinylcarnitine was the
only metabolite that was found to significantly map to the
syntenic region in mouse (P-value of 1.98e-10) (Supplementary
Table S5).”
Alternatively, we also looked at reproducibility of 119 mouse
liver metabolites found to be significantly mapping to 240 loci in
our study by looking at the GWAS results published by Suhre et al
(2011) for single metabolites. From the 119 metabolites 54 metabo-
lites were also measured in the human study. These common
metabolites mapped to 115 distinct loci in mice. For each of these
loci and their corresponding metabolites we asked if a human
syntenic region harbors evidence of association. For the purpose of
this comparison we relaxed the significance criteria in human data
from genome-wide cutoff to any GWAS P-value result ≤ 4.3 × 104
as set by Bonferoni correction for the 115 loci (0.05 divided by 115).
From the 115 total loci, we found evidence of GWAS association for
39% of these loci (45 out of 115) (Supplementary Table S6). Out of
the 45 loci, 40 loci were found in only one of the two populations
(either TwinUK or Kora) and for 5 loci we found significant
evidence in both populations. This included a highly significant
locus on chromosome 9 in mouse for succinylcarnitine. In humans
this metabolite mapped to the syntenic region on chromosome 15
(61.2 Mb) with the GWAS P-values of 6.8e-21and 1.5e-07 in the
KORA and TwinUK populations, respectively. The variation at this
locus in mouse explained 32% of total succinylcarnitine variation in
the HMDP. It is worth noting that, from the four mouse metabolites
mapping to the loci that explained more than 50% of the variations,
one locus (the mouse chromosome 1 locus regulating pyridoxate)
was also found in the syntenic region in the KORA population, with
the P-value of 1.9e-04. We were unable to examine the other three
loci as the metabolites mapping to these loci were not measured in
human.
It has been suggested that mapping metabolite ratios instead
of single metabolites may improve the mapping results in GWAS.
To investigate this, we mapped the metabolite ratios which had
at least one genome-wide significance in the human blood serum
metabolite meta-analysis (Suhre et al, 2011) and asked whether
the mapping results are significantly improved compared to
mapping single metabolite levels. As shown in Supplementary Fig
S3, we found no marked improvement in GWAS results when
ratios of two related metabolites were mapped compared to single
metabolite levels. The only instance in which mapping ratios
resulted in significant result was for the Docosahexaenoate/
Eicosapentaenoate ratio which mapped to the locus on Chromo-
some 14 (Supplementary Fig S3). In addition, none of the highly
significant human loci published for metabolite ratios replicated
for their corresponding metabolite ratios in mice (Supplementary
Table S5).
Correlations between metabolites, transcripts, and clinical traits
In an effort to understand the relationship between gene expression,
metabolite levels, and clinical traits using a “systems genetics”
approach (Civelek & Lusis, 2014), we integrated metabolite levels
with gene expression microarray data and clinical trait data that
were available for the HMDP. We studied the relationship between
transcript and metabolite levels by calculating pair-wise correlations
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between mRNA levels and the metabolites abundance. At the 5%
FDR (P-value of 1.28e-05), we found a total of 1,497 significant
metabolite-mRNA correlations of which 721 (48%) were positive
and 776 (52%) were negative. The 1,497 significant correlations
included 969 probesets on the gene expression microarray and 145
metabolites. To investigate the significance of integrating metabolite
Figure 5. Biological validation of candidate genes.
A Biological validation for the Gpd2 gene and its effect on liver G3P levels. The GWAS results for the G3P metabolite levels and Gpd2 mRNA levels are shown on the top.
On the bottom the results of adenovirus experiments in mice overexpressing Gpd2 (red) and control mice (black) are shown. For each group four mice were used
(n = 4).
B Biological validation for the Acy1 gene and its effect on liver N-acetylglutamate levels. The GWAS results for the N-acetylglutamate metabolite levels and Acy1 mRNA
levels are shown on the top. On the bottom the results of adenovirus experiments in mice overexpressing Acy1 (red) and control mice (black) are shown. For each
group four mice were used (n = 4).
C Biological validation for the Aox1 and its effect on liver pyridoxate levels. The GWAS results for the pyridoxate metabolite levels and Aox1 mRNA levels are shown on
the top. On the bottom the results of adenovirus experiments in mice overexpressing Aox1 (red) and control mice (black) are shown. For each group four mice were
used (n = 4).
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and transcript data, we also correlated each of these molecular
phenotypes with 58 metabolic syndrome related clinical traits
(Supplementary Table S7). The clinical traits utilized in this study
are part of our ongoing effort to collect HMDB phenotypes with the
focus on traits related to cardiovascular and metabolic disorders. At
a cutoff of 5% FDR (P-value = 1e-04), we found 36 significant corre-
lations. These included both known (such as lactate-plasma glucose,
fructose-plasma glucose, 7-beta-hydroxycholesterol-plasma unesteri-
fied cholesterols, and betaine-fat pad mass) and novel metabolite-
trait relations (such as glycerate-bone density, and ascorbate-plasma
total cholesterol levels). Two-dimensional hierarchical clustering of
transcripts against metabolites and clinical traits revealed discrete
clusters of mRNA-metabolite-trait relationships (Supplementary
Fig S4).
Discussion
In the past decade, major efforts have been focused on developing
efficient methods to extract and quantify metabolite profiles from
various tissues (Wang et al, 2010). Several recent reports have
investigated the utility of metabolome in discovering genetic varia-
tions underlying human disease, biomarkers for cancer, and biomar-
kers for pharmacological responses (Gieger et al, 2008; Bain et al,
2009; Illig et al, 2010; Suhre et al, 2011; Wang et al, 2011). One
limitation of the human studies is that these studies mainly
measured metabolites in blood serum. Here, we investigated the
relationships of a large set of metabolites encompassing major meta-
bolic processes in the mouse liver, a central tissue for metabolism.
Overall we were able to map approximately 40% of the metabolites
to at least one locus in the genome. Our study shows that the major-
ity of loci regulating these metabolites accounted for 20–40% of
total metabolite variation and a few (4 loci) accounted for more than
50% variation. This contrasts to loci regulating physiological/clini-
cal traits which generally explain 10% or less of the phenotypes. In
principal, genetic effect sizes are expected to be larger for molecular,
or “intermediate”, phenotypes, such as metabolites or transcript
levels, as compared to clinical phenotypes, and to be larger in exper-
imental organisms, where environmental factors can be reduced as
compared to human studies. The latter may also explain why we
found many more loci regulating metabolite levels in mice
compared to the recent human studies (240 significant loci found in
our study versus 37 in the human report). Moreover, we found
evidence for similarity in genetic regulation of metabolites in mouse
and human for 39% of the loci found to be significant in mice.
However, 61% of loci that were found to be significant in our study
did not replicate in the human published studies. The observed
dissimilarities between the mouse data and the human can be partly
explained by interspecies differences between mouse and human,
and partly by the study design differences where serum metabolites
were mapped in human whereas we report on loci regulating liver
metabolites.
The study described in this manuscript has several limitations.
First, the list of prioritized candidate genes was mainly derived
from the overlapping cis-eQTL data. As this list would only
support genetic variations affecting transcript levels, candidate
genes regulated at the protein level will not be included in this
list. To compensate for that, we queried the prior knowledge from
publicly available databases, but this approach only added mini-
mally to prioritization of candidate genes reflecting our incom-
plete state of knowledge about the genetic factors regulating
metabolite levels and supporting the limited utility of the curated
databases to find potential candidate genes. An alternative
approach to find candidate genes would be to take a network
based approach which would allow for identification of genes
driving network modules comprised of metabolites and other
nodes (i.e. transcripts or clinical traits). Initial studies taking this
integrative approach have proved useful in inferring the drivers of
network module by combining genetic variation with metabolite
and transcriptome data (Inouye et al, 2010).
Another limitation of our study was the use of limited number
of replicates in measuring metabolites for each inbred strain. The
presence of biological replicates among the population of geneti-
cally distinct inbred mice allows one to accurately assess the vari-
ation in metabolites due to genetic factors. However due to
practical limitations we were able to only include five biological
replicates for only one of the strains in our study. Also, since we
used a P-value threshold based on FDR, some of our findings
(12/119 loci) are likely to correspond to false positives. Another
limitation of the current study includes the absence of environ-
mental perturbation. We have shown that in mice physiological
response to environmental perturbations (such as diet) may trig-
ger response differently depending on the genetic make up of the
organism (Parks et al, 2013). In addition, evidence suggests that
in genetically diverse populations diet might be a major factor
accounting for metabolite variation (Holmes et al, 2008). More-
over, metabolites relating to mitochondrial energy metabolism
were found to differentiate gender and age (Slupsky et al, 2007).
In our study we only focused on the effect of natural variation
on liver metabolites in the absence of both sex differences and
environmental perturbations. For future studies, however, the
HMDP population offers an ideal resource to elucidate the extent
of the interaction between environment and genes to regulate
metabolite levels. This resource is also ideal for examining the
effect of age and sex on metabolite profile and our future studies
are aimed at addressing these questions. Lastly, it has been
shown that there is a great within-individual longitudinal varia-
tion compared to population variation in the human urine metab-
olite levels (Nicholson et al, 2011). The design of our study,
however, prevented us from examining such variation within
each mouse as our study was performed on the liver which could
not be resampled over time.
In our study, we found significant intra- and inter-class corre-
lations between metabolites, reflecting shared biochemical path-
ways or regulatory interactions. This was especially true for the
metabolites classified as Lipids, Amino Acids, and Carbohydrates.
The presence of significant correlations between metabolites cate-
gorized in two separate classes presumably reflects either
multiple roles of metabolites or interactions between metabolic
pathways.
Our study highlights the value of integrating data from various
biological scales, such as metabolome, transcriptome, phenome,
and genome. The integration of transcriptome data and the corre-
sponding eQTL profile assisted us in reducing the number of
candidate genes residing under each metabolite locus. The validity
of this approach was highlighted by the biological validation of
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two of the candidate genes identified. In each validation experi-
ment the results were in complete concordance with what we had
found in the GWAS results, both supporting the validity of our
approach and providing a resource that should aid in identifying
the genetic factors affecting metabolite variations. The results of
validation experiments are also consistent with the biochemical
function of the tested candidate genes. Gpd2 is an enzyme that
belongs to the glycerol phosphate shuttle and catalyzes the conver-
sion of glycerol-3-phosphate (G3P) to dihydroxyacetone phosphate.
Therefore, it is expected that the mice with high expression of this
enzyme will have lesser amount of the G3P substrate. This
hypothesis was also supported by the GWAS results and subse-
quently shown to be true by our validation experiment. Interest-
ingly, St-Pierre et al (2001) has published evidence for association
between variation in Gpd2 and free fatty acid concentration in
French Canadians. Accordingly we examined the previously
published free fatty acid GWAS results in HMDP and found a
suggestive LOD score for this trait on chromosome 2 where G3P
and Gpd2 map and where the Gpd2 gene is physically located
(data not shown).
Similarly, our biological validation of Acy1 supported the hypoth-
esis generated by the GWAS results. The GWAS data predicted that
this enzyme was affecting the levels of N-acetylglutamate in the
liver. According to the KEGG pathway database, Acy1 is an interme-
diate enzyme in the biochemical pathway that converts glutamine
to ornithine, with the latter being subsequently utilized in the Urea
Cycle. Therefore, as expected, mice that express higher levels of
Acy1 will be expected to have lower levels of N-acetylglutamate.
Our validation corroborated this expectation and provided a causal
link between variation in Acy1, an intermediate enzyme in the
conversion of glutamine to ornithine, and N-acetylglutamate. Inter-
estingly, the ornithine levels neither mapped to the Acy1 locus nor
were they changed in the mice injected with adenovirus carrying
the Acy1 construct. This perhaps is due to the complex regulation of
ornithine levels in liver, as this metabolite is being used in Urea
Cycle and can be produced by means other than conversion of
glutamine.
In our third validation experiment, Aox1 overexpression, was
predicted to affect pyridoxate levels. Although we did observe a
change in pyridoxate levels consistent with the GWAS data, the
difference did not reach statistical significance. In the GWAS analy-
sis, pyridoxate levels mapped to chromosome 1 at 58 Mb locus with
highly significant P-value of 1.66e-28. A closer examination of this
locus revealed that in addition to Aox1, there are several other
candidate genes, including two other members of the amylase gene
family with local eQTLs in this region.
Overall, our study complements other recent reports in estab-
lishing the influence of genetic variation on metabolites and
provides support for the utility of metabolome integration with
transcriptome to elucidate novel relationships across various
biological scales. Investigation of metabolite levels will clearly be
important in establishing the flow of information that underlies
common diseases. In particular, human GWAS studies have identi-
fied thousands of loci contributing to common diseases, and a
major challenge at present is to understand the pathways that are
perturbed. A “systems genetics” approach as described here should
complement more traditional “one-gene-at-a-time” approaches
(Civelek & Lusis, 2014).
Materials and Methods
Clinical trait measurements
Animals and Clinical Phenotypes: Male mice from the HMDP panel,
approximately 6-10 weeks of age, were purchased from Jackson
Laboratory and were fed Purina Chow (Ralston-Purina Co., St.
Louise, MO) containing 4% fat until sacrifice. All mice were main-
tained on a 12 h light/dark cycle. At 16 weeks of age, whole body
fat, fluids and lean tissue mass of mice were determined using a
Bruker Optics Mini spec nuclear magnetic resonance (NMR)
analyzer (The Woodlands, TX, USA) according to the manufac-
turer’s recommendations. We also calculated the total mass of the
mice, sum of lean mass, free fluid, fat mass, body fat percentage,
and fat mass/total mass. Following a 16-h fast, mice were weighed
and then bled retro-orbitally under isoflurane anaesthesia. Complete
blood counts were performed using a Heska CDC-Diff analyzer
(Heska Corp, Loveland, CO, USA). Plasma lipids were determined
as previously described (Mehrabian et al, 1993). Glucose levels
were determined using commercially available kits from Sigma (St.
Louis, MO, USA). Insulin levels were measured using commercial
ELISA kits (ALPCO Diagnostics). All measurements were performed
in triplicate according to the manufacturer’s instructions. Mice were
euthanized by cervical dislocation and the mass of individual
tissues and fat depots (heart, kidney, retroperitoneal fat pad, epidid-
ymal fat pad, subcutaneous fat pad, and omental fat pad) were
determined by dissecting and weighing each tissue/pad separately
after the mice were euthanized. Following this, liver tissues were
dissected out, flash frozen in liquid nitrogen, and kept at 70°C
until further processing. Bone Mineral Density (BMD) was deter-
mined as previously described (Farber et al, 2011). Plasma Apolipo-
protein levels of ApoA1, ApoA2, ApoA4, ApoB, ApoC2, ApoC3,
ApoD, ApoE, ApoM, Clusterin, LCAT, LpPLA2, PON1, and SAA1
were determined by the Protein Analysis Research Center (PARC) at
Indiana University School of Medicine. Briefly, 100 ll aliquots of
mouse plasma were used to determine apolipoprotein abundance
using an MRM-based targeted proteomic approach. After constant
amount of human apolipoprotein was spiked into each sample, all
apolipoproteins were enriched and digested with trypsin using AB/
SCIEX 4000 QTRAP and Dionex U3000 HPLC system. A microspray
source was used for all the MS analyses. Source temperature was
set at 450°C, and source voltage was set at 5,500 V. Collision
Energy (CE) and Declustering Potential (DP) for each transition
were automatically calculated by the Skyline algorithm. Transitions
for each peptide were averaged for each sample on the log2 Area-
Under-the-Curve (AUC) scale to get a single number for peptide
level for each sample. A relative amount of protein was calculated
against commercially available pooled healthy mouse plasma. The
analysis was carried out using JMP. LCAT activity was measured
using a kit according the manufacturers’ specifications (Roar
Biomedical, Inc., New York, NY). PON activity was determined as
(Shih et al, 1998). Phospholipid Transfer Protein (PLTP) was deter-
mined using a commercially available kit (# P7700 from Roar
Biomedical, Inc., New York).
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal experiments and work were carried
out with UCLA IACUC approval.
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Metabolic profiling
A total of 104 strains were used for metabolite profiling. All mice
were fasted overnight and liver samples were harvested between 10
AM and 12 PM the next day. Liver samples were then shipped to
Metabolon and the profiling was completed in 6 days. For the
majority of strains used in this study we only measured metabolites
in the liver of one mouse per strain. For 20 strains, however, we
profiled more than one mouse per strain. The strains with more
than one mouse profiled includes: AJ, AXB19b, AXB24, B6, BALB/c,
BXA16, BXD19, BXH4, C3H, CXB1, CXB11, CXB12, CXB13, CXB2,
CXB3, CXB4, CXB6, CXB7, CXB8, CXB9, and DBA (all except B6 had
2 mice per strain). For the strains with more than one mouse per
strain, we used the mean of the liver metabolite across the mice to
represent the metabolite value. For the B6 strain, in particular, we
included five mice to estimate the intrastrain (nongenetic) variation.
The non-targeted metabolic profiling instrumentation employed
for this analysis combined three independent platforms: ultrahigh
performance liquid chromatography/tandem mass spectrometry
(UHPLC/MS/MS2) optimized for basic species, UHPLC/MS/MS2
optimized for acidic species, and gas chromatography/mass spec-
trometry (GC/MS). Samples were processed essentially as described
previously (Evans et al, 2009; Ohta et al, 2009). For each sample,
100 ll was used for analyses. Using an automated liquid handler
(Hamilton LabStar, Salt Lake City, UT), protein was precipitated
from the tissue water homogenate with methanol that contained
four standards to report on extraction efficiency. The resulting
supernatant was split into equal aliquots for analysis on the three
platforms. Aliquots, dried under nitrogen and vacuum-desiccated,
were subsequently either reconstituted in 50 ll 0.1% formic acid in
water (acidic conditions) or in 50 ll 6.5 mM ammonium bicarbon-
ate in water, pH 8 (basic conditions) for the two UHPLC/MS/MS2
analyses or derivatized to a final volume of 50 ll for GC/MS analy-
sis using equal parts bistrimethyl-silyl-trifluoroacetamide and
solvent mixture acetonitrile: dichloromethane: cyclohexane (5:4:1)
with 5% triethylamine at 60°C for 1 h. In addition, three types of
controls were analyzed in concert with the experimental samples:
aliquots of a pooled sample derived from a portion of all experimen-
tal samples served as technical replicates throughout the data set,
extracted water samples served as process blanks, and a cocktail of
standards spiked into every analyzed sample allowed instrument
performance monitoring. Experimental samples and controls were
randomized across platform run days.
For UHLC/MS/MS2 analysis, aliquots were separated using a
Waters Acquity UPLC (Waters, Millford, MA) and analyzed using an
LTQ mass spectrometer (Thermo Fisher Scientific, Inc., Waltham,
MA) which consisted of an electrospray ionization (ESI) source and
linear ion-trap (LIT) mass analyzer. The MS instrument scanned 99–
1,000 m/z and alternated between MS and MS2 scans using
dynamic exclusion with approximately six scans per second. Deriva-
tized samples for GC/MS were separated on a 5% phenyldimethyl
silicone column with helium as the carrier gas and a temperature
ramp from 60 to 340°C and then analyzed on a Thermo-Finnigan
Trace DSQ MS (Thermo Fisher Scientific, Inc.) operated at unit mass
resolving power with electron impact ionization and a 50–750
atomic mass unit scan range.
In order to account for run-to-run variation across instruments
and day-to-day variation, well characterized internal standards were
spiked into each sample. The compounds used as internal standards
are chosen so as not to interfere with the measurement of the
endogenous compounds in the sample. In addition, a cocktail of
homogeneous pool containing a small amount of all study samples
served as technical replicates throughout each run. This cocktail
was sent across the GC/MS, and LC/MS/MS2 instruments 5–6 times
per run day as a mechanism to monitor variation within runs and
between runs. The use of technical replicates revealed that the
instrument variability was 5% and overall variability (defined as
within and between run variability) was 9%. To account for such
variability and to standardize data across runs, data were corrected
by registering the median of each run-day to one followed by
normalizing each data point proportionately.
Metabolites were identified by automated comparison of the ion
features in the experimental samples to a reference library of chemi-
cal standard entries that included retention time, molecular weight
(m/z), preferred adducts, and in-source fragments as well as associ-
ated MS spectra, and were curated by visual inspection for quality
control using software developed at Metabolon (Dehaven et al,
2010).
This methodology enabled us to quantify a comprehensive set of
342 metabolites present in mouse liver tissues across the HMDP
panel. In order to minimize false positive associations in our subse-
quent genome-wide association study, we filtered out the metabo-
lites that exhibited significant numbers of missing values (> 20%)
in the samples profiled. As a result, 59 of the metabolites were
filtered out and the remaining 283 metabolites were selected for
further analysis.
RNA isolation and expression profiling
At 16 weeks of age, the liver tissues of the mice were dissected and
flash frozen in liquid nitrogen, and kept at 70°C until further
processing. For RNA profiling, the RNA from three mice per strain
were hybridized to Affymetrix Mouse Genome HT_MG-430A arrays.
Frozen liver samples were weighed and homogenized in Qiazol
according to the manufacturer’s protocol. Following homogeniza-
tion, RNA extraction was performed using Qiagen’s RNeasy kit (cat#
74104). 92 strains of mice had three biological replicates, five strains
had two biological replicates and two strains with one biological
replicate each. All RNA samples were cleaned using a Biosprint96
(Qiagen, Valencia, CA) with RNA cleanup beads (Agencourt Biosci-
ence, Beverly, MA) following manufacturer’s protocol with adapta-
tions for use with the Biosprint. The quality of the total RNA from
the those samples were monitored by the Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA) and RNA quantity was
measured with a NanoDrop (NanoDrop Technologies, Inc., Wilming-
ton, DE) following the manufacturer’s instructions. All samples
were arrayed into three 96-well microtiter plates following a
randomized design format that places samples from the same strain
on different plates to better estimate variance across testing strains.
All target labeling reagents were purchased from Affymetrix (Santa
Clara, CA). Double-stranded cDNAs were synthesized from 1lg total
RNA through reverse transcription with an oligo dT primer contain-
ing the T7 RNA polymerase promoter and double strand conversion
using the cDNA Synthesis System. Biotin-labeled cRNA was gener-
ated from the cDNA and used to probe Affymetrix Mouse Genome
HT_MG-430A arrays. The HT_MG-430A Array plate consists of 96
Molecular Systems Biology 10: 730 | 2014 ª 2014 The Authors
Molecular Systems Biology Genetic regulation of mouse liver metabolites Anatole Ghazalpour et al
10
single MG-430A arrays arranged into standard SBS 96-well plate
format. All cDNA and cRNA target preparation steps were processed
on a Caliper GeneChip Array Station from Affymetrix. Array hybrid-
ization, washing and scanning were performed according to the
manufacturer’s recommendations. Scanned images were subjected
to visual inspection and a chip quality report was generated by the
Affymetrix’s GeneChipOperating System (GCOS) and Expression
console (Affymetrix). Two of 288 chips were excluded due to low
QC scores. The image data was processed using the Affymetrix
GCOS algorithm utilizing quantile normalization or the Robust
Multiarray method (RMA) to determine the specific hybridizing
signal for each gene. Expression data can be obtained from Geo
database (GSE16780). To avoid the effect of SNP on hybridization,
we matched the location of approximately 14 million SNPs from
dbSNP database (NCBI) to the location of the individual probes on
the genome. If the location of the probe had a matching SNP within
it, we flagged the probe and excluded it from the cdf file prior to
RMA normalization. If a probeset contained SNP in 8 or more
25-mer probes, we excluded the probeset from the analysis. The
cleaned datasets were then background corrected and normalized
using the affy package (from bioconductor) using rma, pmonly, and
median-polish normalization methods.
Genotyping and genome-wide association mapping
Inbred strains were previously genotyped by the Broad Institute
(http://www.broadinstitute.org/mouse/hapmap), and they were
combined with the genotypes from Wellcome Trust Center for
Human Genetics (WTCHG). Genotypes of RI strains at the Broad
SNPs were inferred from WTCHG genotypes by interpolating alleles
at polymorphic SNPs among parental strains, calling ambiguous
genotypes missing. Of the 140,000 SNPs available, 107,145 were
informative with an allele frequency > 5%. These SNPs were used
for metabolite, transcript, and clinical trait genome-wide association
analysis.
We applied the following linear mixed model to account for the
population structure and genetic relatedness among strains in the
genome-wide association mapping (Kang et al, 2008a,b):
y ¼ lþ xbþ uþ e
In the formula, l represents mean, x represents SNP effect, u
represents random effects due to genetic relatedness with Var
(u) = rg2K and Var(e) = re2, where K represents IBS (identity-by-
state) matrix across all genotypes in the HMDP panel. A restricted
maximum likelihood (REML) estimate of rg2 and re2 are computed
using EMMA, and the association mapping is performed based on
the estimated variance component with a standard F-test to test
b 6¼ 0. We applied Efficient Mixed Model Association (EMMA) as an
R implementation of a linear mixed model. The percent of variance
explained for each molecular phenotype was calculated using the
SNP effect calculated from EMMA by defining it as: 1  [(variance
of residuals)/(variance of original phenotypes)]. It should be noted
that since EMMA is orders of magnitude faster than other implemen-
tations commonly used, we were able to perform statistical analyses
for all pairs of transcripts/metabolites and genome wide markers in
a few hours using a cluster of 50 processors.
The “peak SNP” reported for each metabolite was identified by
first finding all the SNPs that exceeded the genome-wide cutoff for
that particular metabolite. Next, SNPs were ordered by the strength
of association, and among the ranked SNPs the SNP R-squares were
calculated. Among the SNPs that had R-square > 0.5, only the SNP
that showed the strongest association was kept and reported as the
“peak SNP” in the manuscript. To look for candidate genes for each
metabolites, we took each metabolite’s “peak SNP” at each signifi-
cant locus and searched for the presence of local eQTL in the inter-
val spanning from 1 Mb proximal to 1 Mb distal to the metabolite
peak SNP. eQTL were defined as “local” if the peak association SNP
position for the transcript was within a 4 Mb interval, flanking
2 Mb on either side of the transcription start and end of the gene
under regulation.
Genome-wide cutoff: Genome-wide cutoffs were calculated as
the false discovery rates using the “q-value” package for FDR calcu-
lation in the R statistical software (Storey & Tibshirani, 2003). FDR
calculation was carried out separately for the metabolites and tran-
script dataset. For transcript data, due to the computational
complexity associated with evaluating q-values for over 400 million
P-values, we computed the FDRs by taking the average FDR for 100
samples each containing 5 million randomly selected P-values from
the original calculated P-values. The FDR threshold is similar to that
calculated in the HMDP population using simulation or a Bonferroni
correction for SNPs examined(Bennett et al, 2010). The fact that it
is larger than the usual human GWAS threshold reflect the fact that
the linkage disequilibrium blocks in the HMDP are larger than those
in human populations(Bennett et al, 2010; Parks et al, 2013).
Adenovirus generation, purification and infection in vivo
Recombinant adenovirus was generated using the AdEasy system as
previously described (Bennett et al, 2013). Briefly, linearized shuttle
vector containing full-length mouse cDNA for each of the three
candidate genes (Gpd2, Acy1, and Aox1) was transformed into
E. coli BJ5183AD cells containing the adenoviral backbone plasmid
pAdEasy-1 for homologous recombination. Positive recombinants
were linearized and transfected into HEK293AD cells for virus pack-
aging and propagation. Adenoviruses expressing the candidate gene
were purified by CsCl banding and stored at 80°C until use. For
adenoviral infection, 10-week-old male C57BL/6 mice were injected
with adenoviral construct (~2 × 109 PFUs diluted in 0.2 ml saline)
through the tail vein. After overnight fasting, mice were sacrificed
6 days post injection, the liver tissue was extracted, the expression
of each candidate gene was assessed by RT-PCR, and the metabo-
lites were profiled by Metabolon, Inc (Durham, NC). For each candi-
date gene, we utilized four mice (n = 4). The control group
consisted of mice injected with adenoviral construct expressing the
LacZ gene.
Other statistical methods/Software
The z-scores for each metabolite in each mouse was calculated using
standard formula: z-score = (relative metabolite level in the sample –
mean of metabolite level in the samples)/standard deviation of
metabolite levels in the samples. The calculated z-scores were used
both in genome-wide association and in correlation analysis.
Public databases utilized to pair metabolites with genes were
Kyoto Encyclopedia of Genes and Genomes (KEGG) at http://
www.genome.jp/kegg and Human Metabolome Database (HMDB)
at www.hmdb.ca (Wishart et al, 2009). For KEGG, we searched the
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pathways specific to mouse. HMDB, however, is a freely available
electronic database containing detailed information about small
molecule metabolites found in the human body. To translate the
information to mouse, we downloaded all the relationships docu-
mented between small molecules and genes in HMDB version 2.5
and converted all the human genes to mouse orthologous genes.
The resulting mouse gene-small molecule file was then used
throughout the paper.
All statistical analyses, database annotation, and data visualiza-
tions were carried out using the R (version 2.13.1) statistical soft-
ware (available at http://cran.r-project.org/) and Python 3.0
(http://python.org/). All the correlation coefficients and corre-
sponding P-values reported in the paper are calculated using the
bicor function in the WGCNA R package (Langfelder & Horvath,
2008) The main advantage of using bicor, which performs biweight
midcorrelation calculation, over Pearson’s correlation is based the
robustness of the correlation coefficient measurement to the pres-
ence of outliers in the data.
Data accessibility
All the genome-wide significant mapping results for metabolites
along with the candidate genes regulating each metabolite are
provided in Supplementary Tables and deposited in our website at
http://systems.genetics.ucla.edu. In addition, the liver metabolite
data from this publication have been submitted to the Mouse
Phenome Database at http://phenome.jax.org and assigned the
identifiers HMDPpheno6, HMDPpheno7, HMDPpheno8, HMDPphe-
no9, and HMDPpheno10. Liver mouse transcript data are deposited
to the GEO at http://www.ncbi.nlm.nih.gov/geo/ and assigned the
identifier GSE16780.
Supplementary information for this article is available online:
http://msb.embopress.org
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